Skip to main content

VivoSim Labs, INC.

VIVS
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001497253

In the last 90 days, VivoSim Labs, INC. insiders filed 1 open-market purchase and 0 sales; 25 institutions reported holding it in 13F filings for Q3 2026, worth $109.7K in total; no superinvestor holds it.

Currency
USD
Source
SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
Updated
Nov 13, 2026, 1:19 AM ET

Revenue flow, FY2026

Where the revenue went in FY2026, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.

Net loss for FY2026: $13.8M (10567.2% of revenue).

Income statement

Each column is one fiscal year, newest first.

Income statement of VivoSim Labs, INC., annual
Line itemFY2026FY2025FY2024FY2023FY2022
Period endMar 31, 2026Mar 31, 2025Mar 31, 2024Mar 31, 2023Mar 31, 2022
Filing10-K10-K10-K10-K10-K
Reported–Apr 2, 2025–––
Revenue$131.0K$144.0K$109.0K$370.0K$1.50M
Cost of revenue$0$5.00K–––
Research and development$4.19M$5.03M$5.50M$8.88M$3.32M
Selling, general and administrative$7.43M$7.73M$9.70M$9.22M$9.66M
Operating income-$11.5M-$12.6M-$15.1M-$17.7M-$11.5M
Income tax$2.00K$2.00K$2.00K$2.00K$2.00K
Net income-$13.8M-$2.49M-$14.7M-$17.3M-$11.4M
EPS, basic$-5.35$-1.70$-1.60$-1.98–
EPS, diluted$-5.35$-1.70$-1.60$-1.98–
Weighted shares, basic2.59M1.46M9.14M8.71M–
Weighted shares, diluted2.59M1.46M9.14M8.71M–
Margins and growth
Operating margin-8768.7%-8761.1%-13840.4%-4792.2%-765.3%
Net margin-10567.2%-1727.8%-13459.6%-4664.6%-763.2%
Revenue growth, year over year−9.0%+32.1%−70.5%−75.3%–

Balance sheet

Each column is one fiscal year, newest first.

Balance sheet of VivoSim Labs, INC., annual
Line itemFY2026FY2025FY2024FY2023FY2022
Period endMar 31, 2026Mar 31, 2025Mar 31, 2024Mar 31, 2023Mar 31, 2022
Filing10-K10-K10-K10-K10-K
Reported–Apr 2, 2025–––
Cash and equivalents$5.02M$11.3M$2.90M$15.3M$28.7M
Accounts receivable$32.0K$30.0K$33.0K$152.0K–
Inventory–$0$297.0K––
Total current assets$6.63M$12.1M$3.94M$17.0M$29.5M
Property, plant and equipment$206.0K$419.0K$669.0K$902.0K$662.0K
Total assets$7.39M$14.7M$6.35M$20.3M$33.3M
Accounts payable$1.02M$1.64M$627.0K$331.0K$415.0K
Total current liabilities$2.79M$3.74M$1.86M$3.67M$1.38M
Total liabilities$8.48M$4.16M$2.75M$4.98M$3.09M
Shareholders' equity-$1.10M$10.5M$3.60M$15.3M$30.2M

Cash flow statement

Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.

Cash flow statement of VivoSim Labs, INC., annual
Line itemFY2026FY2025FY2024FY2023FY2022
Period endMar 31, 2026Mar 31, 2025Mar 31, 2024Mar 31, 2023Mar 31, 2022
Filing10-K10-K10-K10-K10-K
Reported–Apr 2, 2025–––
Operating cash flow-$10.8M-$9.46M-$14.7M-$12.4M-$8.45M
Capital expenditures$0$13.0K$42.0K$396.0K$409.0K
Free cash flow-$10.8M-$9.47M-$14.7M-$12.8M-$8.86M
Depreciation and amortization$215.0K$266.0K$280.0K$293.0K$142.0K
Stock-based compensation$303.0K$532.0K$1.51M$2.38M$2.26M
Share buybacks––––$0
Investing cash flow$94.0K$9.03M$816.0K-$966.0K-$409.0K
Financing cash flow$4.45M$8.85M$1.44M$0$205.0K
Net change in cash-$6.29M$8.41M-$12.4M-$13.4M-$8.66M
Ratio
Stock-based compensation, % of revenue231.3%369.4%1383.5%642.4%150.4%

Shares outstanding

Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.

Shares outstanding for VivoSim Labs, INC. by cover date
Cover dateShares outstandingChange in a yearFiling
Nov 1, 202620.3M+677.7%SEC
Aug 10, 202614.9M+471.2%SEC
Jul 10, 20263.49M+34.4%SEC
Feb 1, 20262.61M−85.1%SEC
Nov 1, 20252.61M−83.0%SEC
Aug 1, 20252.60M−83.1%SEC
Jun 1, 20252.60M−81.9%SEC
Feb 1, 202517.5M+73.8%SEC

Notes and known gaps

How these numbers are put together, and what they can't tell you.

  • Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
  • Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.

Known gaps

  • Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
  • EPS and share counts are as reported at the time, not adjusted for later stock splits. Stock splits since Mar 31, 2021, from 13F share counts: 1-for-12 in Q1 2025.
  • For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
  • For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
  • Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
  • Depreciation and amortization is missing for some companies that report it under their own XBRL tags.